

2023 Publications

Spherix Global Insights

info@spherixglobalinsights.com

484.879.4284



MARKET DYNAMIX

Market Dynamix™ is an independent service providing analysis of markets anticipated to experience a paradigm shift within the next three to five years, highlighting market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.

Methodology: Insights are based on analyses of quantitative data collected from an online survey of specialists, patients, and leading KOLs recruited from the Spherix Network, as well as qualitative interviews conducted with a subset of survey respondents and select KOLs.

Sample Size & Frequency

- US: annual report (n=100 physicians)
- EU5: annual report (n=200 physicians)
- Qualitative interviews (n=6-8 physicians, n=1-2 KOLs)

LAUNCH DYNAMIX

Launch Dynamix™ is an independent service providing a monthly benchmarking of newly launched products for the first eighteen months of commercial availability, augmented by a quarterly deep dive into patient types initiated, brand perceptions, promotional activity, and drivers and barriers to uptake.

Methodology: Insights are based on analyses of quantitative data collected from an online survey of physicians “in the trenches” recruited from the Spherix Network, as well as qualitative interviews conducted with a subset of survey respondents.

Sample Size & Frequency

- Monthly KPI dashboard (n=75 physicians)
- Quarterly report (n=75 physicians)
- Quarterly qualitative interviews (n=8 physicians)



REALTIME DYNAMIX

RealTime Dynamix™ is an independent service providing strategic guidance through quarterly or semiannual reports, which include market trending and a fresh infusion of event-driven and variable content with each wave. The reports provide an unbiased view of the competitive landscape within rapidly evolving specialty markets, fueled by robust HCP primary research and our in-house team of experts.

Methodology: Insights are based on data collected from an online survey of respondents recruited from the Spherix Network, a proprietary group of specialty physicians in clinical practice meeting quality screening criteria.

Sample Size & Frequency

- US: quarterly report (n=100 respondents)
- EU5: semiannual report (n=250 respondents)
- Canada: semiannual report (n=50 respondents)

REALWORLD DYNAMIX

RealWorld Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits. Insights reveal the “why” behind treatment decisions, include year over year trending to quantify key aspects of market evolution, and integrate specialists’ attitudinal & demographic data to highlight differences between stated and actual treatment patterns.

Methodology: Insights are based on patient level data gathered through collaboration with specialty physicians who provide details on clinical and non-clinical patient demographics, along with their rationale for treatment choices.

Sample Size & Frequency

- US: annual patient chart audit (n=1,000 charts, n=200 physicians)
- EU5: annual patient chart audit (n=1,250 charts, n=250 physicians)



SPECIAL TOPIX

Special Topix™ is an independent service that includes access to a report or series of reports based on current events or topics of interest in specialty markets covered by Spherix.

Methodology: Insights are based on data collected from an online survey of respondents recruited from the Spherix Network, a proprietary group of specialty physicians in clinical practice meeting quality screening criteria.

Sample Size & Frequency

- Report cadence and deliverable depend upon current event/topic being evaluated



Atopic Dermatitis

REALTIME DYNAMIX

- *Atopic Dermatitis (US)*
- *Atopic Dermatitis (EU)*

LAUNCH DYNAMIX

- *Adbry (LEO) in Atopic Dermatitis (US)*
- *Cibinqo (Pfizer) in Atopic Dermatitis (US)*
- *Opzelura (Incyte) in Atopic Dermatitis (US)*
- *Rinvoq (AbbVie) in Atopic Dermatitis (US)*
- *Etrasimod (Pfizer) in Atopic Dermatitis (US)**
- *Lebrikizumab (Eli Lilly) in Atopic Dermatitis (US)**
- *Vtama (Dermavant) in Atopic Dermatitis (US)**
- *Zoryve (Arcutis) in Atopic Dermatitis (US)**

REALWORLD DYNAMIX

- *Advanced Systemics in Atopic Dermatitis (US)*
- *Advanced Systemics in Atopic Dermatitis (EU)*

Plaque Psoriasis

REALTIME DYNAMIX

- *Plaque Psoriasis (US)*
- *Plaque Psoriasis (EU)*

LAUNCH DYNAMIX

- *Sotyktu (BMS) in Psoriasis (US)*
- *Vtama (Dermavant) in Psoriasis (US)*
- *Zoryve (Arcutis) in Psoriasis (US)*
- *Bimzelx (UCB) in Psoriasis (US)**
- *Sonelokimab (MoonLake/Merck) in Psoriasis (US)**

REALWORLD DYNAMIX

- *Biologic/Small Molecule Switching in Psoriasis (US)*

*Pending approvals and launch

Note: Services may change due to factors such as FDA approval status and other market events



Emerging Dermatology

MARKET DYNAMIX

- Alopecia Areata (US)
- Alopecia Areata (EU)
- Hidradenitis Suppurativa (US)
- Hidradenitis Suppurativa (EU)
- Prurigo Nodularis (US)
- Vitiligo (US)

LAUNCH DYNAMIX

- Dupixent (Sanofi/Regeneron) in Prurigo Nodularis (US)
- Olumiant (Eli Lilly) in Alopecia Areata (US)
- Opzelura (Incyte) in Vitiligo (US)
- Cosentyx (Novartis) in Hidradenitis Suppurativa (US)*
- Deuruxolitinib (Concert) in Alopecia Areata (US)*
- Nemolizumab (Galderma) in Prurigo Nodularis (US)*
- Ritlecitinib (Pfizer) in Alopecia Areata (US)*
-

REALWORLD DYNAMIX

- Alopecia Areata (US)
- Hidradenitis Suppurativa (US)

SPECIAL TOPIX

- Biosimilars Today and Tomorrow - Dermatology (US)
- Fellows and Residents - Dermatology (US)
- Impact of Inflation and COVID-19 on Specialty Practices - A Cross Specialty Analysis (US)

*Pending approvals and launch

Note: Services may change due to factors such as FDA approval status and other market events



Inflammatory Bowel Disease

REALTIME DYNAMIX

- Crohn's Disease (US)
- Crohn's Disease (EU)
- Ulcerative Colitis (US)
- Ulcerative Colitis (EU)

LAUNCH DYNAMIX

- Rinvoq (AbbVie) in Ulcerative Colitis (US)
- Skyrizi (AbbVie) in Crohn's Disease (US)
- Etrasimod (Arena) in Ulcerative Colitis (US)*
- Mirikizumab (Eli Lilly) in Ulcerative Colitis (US)*
- Rinvoq (AbbVie) in Crohn's Disease (US)*

REALWORLD DYNAMIX

- Biologic/Small Molecule New Starts in IBD (US)
- Biologic/Small Molecule Switching in IBD (US)
- Biologic/Small Molecule Switching in IBD (EU)

Eosinophilic Esophagitis

MARKET DYNAMIX

- Eosinophilic Esophagitis (US)

LAUNCH DYNAMIX

- Dupixent (Sanofi/Regeneron) in Eosinophilic Esophagitis (US)
- APT-1011 (Ellodi) in Eosinophilic Esophagitis (US)*

REALWORLD DYNAMIX

- Treatment New Starts and Switching in Eosinophilic Esophagitis (US)

Emerging Gastroenterology

MARKET DYNAMIX

- Clostridioides Difficile (US)
- Nonalcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis (US)

LAUNCH DYNAMIX

- Ibsrela (Ardelyx) in Irritable Bowel Syndrome with Constipation (US)
- CP101 (Finch) in Clostridium Difficile Infection (US)*
- RBX2660 (Ferring/Rebiotix) in Clostridium Difficile Infection (US)*
- Ridinilazole (Summit) in Clostridium Difficile Infection (US)*
- SER109 (Seres) in Clostridium Difficile Infection (US)*
- Lanifibranor (Inventiva) in Non-Alcoholic Fatty Liver Disease*
- Oclavia (Intercept) in Non-Alcoholic Fatty Liver Disease*
- Resmitirom (Madrigal) in Non-Alcoholic Fatty Liver Disease*

SPECIAL TOPIX

- Biosimilars Today and Tomorrow - Gastroenterology (US)
- Fellows and Residents - Gastroenterology (US)
- Impact of Inflation and COVID-19 on Specialty Practices - A Cross Specialty Analysis (US)

*Pending approvals and launch

Note: Services may change due to factors such as FDA approval status and other market events



Kidney Disease

REALTIME DYNAMIX

- CKD and DKD (US)
- Hyperkalemia (US)

LAUNCH DYNAMIX

- Kerendia (Bayer) in Diabetic Kidney Disease (US)
- Korsuva (CSL Vifor) in CKD-associated Pruritus (US)

REALWORLD DYNAMIX

- Chronic Kidney Disease, Non-Dialysis (US)
- Chronic Kidney Disease, Non-Dialysis (EU)
- Dialysis (US)
- Dialysis (EU)

MARKET DYNAMIX

- ADPKD (US)
 - Diabetic Kidney Disease: Cross-Specialty Perspective (US)
-

Anemia

REALTIME DYNAMIX

- Anemia of CKD (US)
- Anemia of CKD (EU)

LAUNCH DYNAMIX

- Jesduvroq (GSK) in Anemia of CKD (US)*
-

Bone and Mineral Metabolism

REALTIME DYNAMIX

- Bone and Mineral Metabolism (US)
- Renal Dietitians (US)

LAUNCH DYNAMIX

- Tenapanor (Ardelyx) in Hyperphosphatemia (US)*
- Tenapanor (Ardelyx) in Hyperphosphatemia - Renal Dietitian Perspectives (US)*

*Pending approvals and launch

Note: Services may change due to factors such as FDA approval status and other market events



Glomerular Diseases

MARKET DYNAMIX

- *Focal Segmental Glomerulosclerosis (US)*
- *IgA Nephropathy (US)*
- *IgA Nephropathy (EU)*
- *IgA Nephropathy (Japan)*
- *Rare Glomerular Diseases (EU)*
- *Rare Glomerular Diseases (Japan)*

LAUNCH DYNAMIX

- *Tarpeyo (Calliditas) in IgA Nephropathy (US)*
- *Sparsentan (Travere) in IgA Nephropathy (US)**

REALWORLD DYNAMIX

- *Complement 3 Glomerulopathy (EU)*
- *Focal Segmental Glomerulosclerosis (US)*
- *IgA Nephropathy (US)*
- *IgA Nephropathy (EU)*
- *IgA Nephropathy (China)*
- *IgA Nephropathy (Japan)*

Lupus Nephritis

REALTIME DYNAMIX

- *Lupus Nephritis (US)*

REALWORLD DYNAMIX

- *Lupus Nephritis (US)*

SPECIAL TOPIX

- *Feedback from ASN Kidney Week 2023 (US)*
- *Fellows and Residents - Nephrology (US)*
- *Impact of Inflation and COVID-19 on Specialty Practices - A Cross Specialty Analysis (US)*
- *Reactions to FDA Advisory Committees and Decisions (as necessary)*

*Pending approvals and launch

Note: Services may change due to factors such as FDA approval status and other market events



Generalized Myasthenia Gravis

MARKET DYNAMIX

- *Generalized Myasthenia Gravis (US)*
- *Generalized Myasthenia Gravis (EU)*

LAUNCH DYNAMIX

- *Vyvgart (Argenx) and Ultomiris (Alexion) in Generalized Myasthenia Gravis (US)*
- *Rozanolixizumab (UCB) in Generalized Myasthenia Gravis (US)**
- *SC Efgartigimod alfa (Argenx) in Generalized Myasthenia Gravis (US)**
- *Zilucoplan (UCB) in Generalized Myasthenia Gravis (US)**

REALWORLD DYNAMIX

- *Generalized Myasthenia Gravis (US)*
-

Migraine

REALTIME DYNAMIX

- *Migraine (US)*
- *Migraine - PCP Perspective (US)*
- *Migraine (EU)*

LAUNCH DYNAMIX

- *Qulipta (Allergan/AbbVie) in Migraine (US)*
- *Trudhesa (Impel) in Acute Migraine (US)*
- *Zavegepant (Pfizer/Biohaven) in Acute Migraine (US)**

REALWORLD DYNAMIX

- *Preventive Treatment in Migraine (US)*
-

Multiple Sclerosis

REALTIME DYNAMIX

- *Multiple Sclerosis (US)*
- *Multiple Sclerosis (Canada)*

LAUNCH DYNAMIX

- *Briumvi (TG Therapeutics) in RMS (US)*

REALWORLD DYNAMIX

- *DMT New Starts in Multiple Sclerosis (US)*
- *DMT Switching in Multiple Sclerosis (US)*

*Pending approvals and launch

Note: Services may change due to factors such as FDA approval status and other market events



Emerging Neurology

MARKET DYNAMIX

- *Amyotrophic Lateral Sclerosis (US)*
- *Early Alzheimer's Disease (US)*
- *Huntington's Disease (US)*
- *Parkinson's Disease (US)*
- *Sleep Disorders (US)*

LAUNCH DYNAMIX

- *Relyvrio (Amylyx) in Amyotrophic Lateral Sclerosis (US)*
- *Donanemab (Eli Lilly) in Alzheimer's Disease (US)**
- *Leqembi (Eisai/Biogen) in Alzheimer's Disease (US)**
- *Tofersen (Biogen) in Amyotrophic Lateral Sclerosis (US)**
- *Ultomiris (Alexion) in Neuromyelitis Optica Spectrum Disorder (US)*

SPECIAL TOPIX

- *Accelerated Approvals in Early Alzheimer's Disease - Leqembi*
- *Impact of Inflation and COVID-19 on Specialty Practices - A Cross Specialty Analysis (US)*

**Pending approvals and launch*

Note: Services may change due to factors such as FDA approval status and other market events



Neovascular Age-Related Macular Degeneration

REALTIME DYNAMIX

- *Neovascular Age-Related Macular Degeneration (US)*

LAUNCH DYNAMIX

- *Vabysmo (Roche/Genentech) in Age-Related Macular Degeneration (US)*
- *8 mg aflibercept in Age-Related Macular Degeneration (Regeneron) (US)*

REALWORLD DYNAMIX

- *New Starts in Neovascular Age-Related Macular Degeneration (US)*
 - *Treatment Switching in Neovascular Age-Related Macular Degeneration (US)*
-

Diabetic Macular Edema

REALTIME DYNAMIX

- *Diabetic Macular Edema (US)*

LAUNCH DYNAMIX

- *Vabysmo (Roche/Genentech) in Diabetic Macular Edema (US)*
- *8 mg aflibercept in Diabetic Macular Edema (Regeneron) (US)*

REALWORLD DYNAMIX

- *Treatment Switching Diabetic Macular Edema (US)*



Diabetic Retinopathy

REALTIME DYNAMIX

- *Diabetic Retinopathy (US)*

REALWORLD DYNAMIX

- *New Starts in Diabetic Retinopathy (US)*
 - *Treatment Switching in Diabetic Retinopathy (US)*
-

Emerging Ophthalmology

MARKET DYNAMIX

- *Geographic Atrophy (US)*
- *Thyroid Eye Disease (US)*

LAUNCH DYNAMIX

- *Pegcetacoplan (Apellis) in Geographic Atrophy (US)**
- *Byooviz (Samsung Bioepis/Biogen) and Cimerli (Coherus) Ranibizumab Biosimilar (US)*

SPECIAL TOPIX

- *Biosimilars Today and Tomorrow - Ophthalmology (US)*
- *Impact of Inflation and COVID-19 on Specialty Practices - A Cross Specialty Analysis (US)*

**Pending approvals and launch*

Note: Services may change due to factors such as FDA approval status and other market events



Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis

REALTIME DYNAMIX

- *Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis (US)*
- *Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis (EU)*

LAUNCH DYNAMIX

- *Rinvoq (AbbVie) in Ankylosing Spondylitis (US)*
- *Rinvoq (AbbVie) in Non-Radiographic Axial Spondyloarthritis (US)*
- *Xeljanz (Pfizer) in Ankylosing Spondylitis (US)*
- *Bimzelx (UCB) in Ankylosing Spondylitis (US)**
- *Bimzelx (UCB) in Non-Radiographic Axial Spondyloarthritis (US)**

Psoriatic Arthritis

REALTIME DYNAMIX

- *Psoriatic Arthritis (US)*
- *Psoriatic Arthritis (EU)*

LAUNCH DYNAMIX

- *Rinvoq (AbbVie) in Psoriatic Arthritis (US)*
- *Skyrizi (AbbVie) in Psoriatic Arthritis (US)*
- *Bimzelx (UCB) in Psoriatic Arthritis (US)**

REALWORLD DYNAMIX

- *Biologic/Small Molecule Switching in Psoriatic Arthritis (US)*

Rheumatoid Arthritis

REALTIME DYNAMIX

- *Rheumatoid Arthritis (US)*
- *Rheumatoid Arthritis (EU)*

LAUNCH DYNAMIX

- *Artelgia (R-Pharm) in Rheumatoid Arthritis (US)**

REALWORLD DYNAMIX

- *Biologic/Small Molecule Switching in Rheumatoid Arthritis (US)*

*Pending approvals and launch

Note: Services may change due to factors such as FDA approval status and other market events



Lupus

REALTIME DYNAMIX

- *Lupus Nephritis (US)*
- *Systemic Lupus Erythematosus (US)*
- *Systemic Lupus Erythematosus (EU)*

LAUNCH DYNAMIX

- *Saphnelo (AstraZeneca) in Systemic Lupus Erythematosus (US)*

REALWORLD DYNAMIX

- *Lupus Nephritis (US)*
- *Moderate to Severe Systemic Lupus Erythematosus (US)*
- *Moderate to Severe Systemic Lupus Erythematosus (EU)*

MARKET DYNAMIX

- *Lupus Subtypes: DLE and CLE*

SPECIAL TOPIX

- *Patient Dynamics in Systemic Lupus Erythematosus (US)*

Emerging Rheumatology

MARKET DYNAMIX

- *Giant Cell Arteritis (US)*
- *Polymyalgia Rheumatica (US)*
- *Sjögren's Syndrome (US)*

LAUNCH DYNAMIX

- *Kevzara (Sanofi/Regeneron) in Polymyalgia Rheumatica (US)*

SPECIAL TOPIX

- *Biosimilars Today and Tomorrow - Rheumatology (US)*
- *Fellows and Residents - Rheumatology (US)*
- *Impact of Inflation and COVID-19 on Specialty Practices - A Cross Specialty Analysis (US)*

About Spherix Global Insights

Spherix Global Insights is a leading provider of market research, business intelligence and advisory services to the global life sciences industry. The company's unique service offerings are powered by deep therapeutic knowledge, the Spherix Network specialty physician panel, and commercially relevant analyses to enable strategic decision-making by our valued customers.

A trusted advisor and industry thought leader, Spherix Global Insights provides specialized market expertise in six (6) focused therapeutic areas including: dermatology, gastroenterology, nephrology, neurology, rheumatology and ophthalmology.

To learn more about Spherix Global Insights, visit spherixglobalinsights.com

For more information and pricing on our services, contact us at 484.879.4284 or info@spherixglobalinsights.com
Visit our website at www.spherixglobalinsights.com

SPHERIX
GLOBAL INSIGHTS